FASN and cancer: LPA has been shown to induce a glycolytic shift in cancer cells, while studies also reveal that it elicits pro-lipogenic actions in ovarian cancer by transcriptionally up-regulating SREBP-FASN and dephosphorylation of AMPK-ACC pathways, which is mediated by an LPA receptor LPA2 (135, 136).